Literature DB >> 1597483

Endocytosis of different members of the small chondroitin/dermatan sulfate proteoglycan family.

H Hausser1, B Ober, E Quentin-Hoffmann, B Schmidt, H Kresse.   

Abstract

The family of small interstitial chondroitin/dermatan sulfate proteoglycans consists of at least three different molecular species: biglycan (proteoglycan I), decorin (proteoglycan II), and proteoglycan-100, which has a glycosylated core protein of about 100 kDa. The core protein of decorin has been shown to be responsible for receptor-mediated endocytosis of this proteoglycan species by a variety of mesenchymal cells. It is now demonstrated that skin fibroblasts and articular chondrocytes endocytose biglycan with an efficiency similar to that of decorin. Uptake of biglycan is also mediated by its core protein and can be inhibited by decorin in a partially competitive manner. In human fibroblasts, endosomal proteins of 51 and 26 kDa, which are known to bind decorin core protein, also interact with biglycan. This interaction can be inhibited by decorin. Bovine articular chondrocytes contained binding proteins of 48 and 25 kDa. Proteoglycan-100 can be distinguished from biglycan and decorin by its low clearance rate, which however, exceeds the rate of fluid phase endocytosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597483

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin.

Authors:  Liliana Schaefer; Wasiliki Tsalastra; Andrea Babelova; Martina Baliova; Jens Minnerup; Lydia Sorokin; Hermann-Josef Gröne; Dieter P Reinhardt; Josef Pfeilschifter; Renato V Iozzo; Roland M Schaefer
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Decorin endocytosis: structural features of heparin and heparan sulphate oligosaccharides interfering with receptor binding and endocytosis.

Authors:  H Hausser; H Kresse
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

Review 3.  Small proteoglycans.

Authors:  H Kresse; H Hausser; E Schönherr
Journal:  Experientia       Date:  1993-05-15

4.  Protein turnover during in vitro tissue engineering.

Authors:  Qiyao Li; Zhen Chang; Gisele Oliveira; Maiyer Xiong; Lloyd M Smith; Brian L Frey; Nathan V Welham
Journal:  Biomaterials       Date:  2015-12-14       Impact factor: 12.479

5.  Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions.

Authors:  Jane Sottile; Denise C Hocking
Journal:  Mol Biol Cell       Date:  2002-10       Impact factor: 4.138

6.  Fibronectin matrix turnover occurs through a caveolin-1-dependent process.

Authors:  Jane Sottile; Jennifer Chandler
Journal:  Mol Biol Cell       Date:  2004-11-24       Impact factor: 4.138

7.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages.

Authors:  Liliana Schaefer; Andrea Babelova; Eva Kiss; Heinz-J Hausser; Martina Baliova; Miroslava Krzyzankova; Gunther Marsche; Marian F Young; Daniel Mihalik; Martin Götte; Ernst Malle; Roland M Schaefer; Hermann-Josef Gröne
Journal:  J Clin Invest       Date:  2005-07-14       Impact factor: 14.808

8.  Proteoglycans and catabolic products of proteoglycans present in ligament.

Authors:  Mirna Z Ilic; Phillip Carter; Alicia Tyndall; Jayesh Dudhia; Christopher J Handley
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

9.  Differences in decorin expression by papillary and reticular fibroblasts in vivo and in vitro.

Authors:  E Schönherr; L A Beavan; H Hausser; H Kresse; L A Culp
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

10.  Immunohistochemical characterization of the small proteoglycans decorin and proteoglycan-100 in heterotopic ossification.

Authors:  A Bosse; H Kresse; K Schwarz; K M Müller
Journal:  Calcif Tissue Int       Date:  1994-02       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.